PLSE
Pulse Biosciences Inc

2,038
Mkt Cap
$1.41B
Volume
2.84M
52W High
$22.75
52W Low
$12.56
PE Ratio
-18.28
PLSE Fundamentals
Price
$21.91
Prev Close
$13.69
Open
$14.95
50D MA
$14.25
Beta
1.31
Avg. Volume
165,658.80
EPS (Annual)
-$0.9176
P/B
15.16
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up - Still a Buy...
MarketBeat·22h ago
News Placeholder
More News
News Placeholder
Pulse Biosciences Presents Late-Breaking Data from nPulse Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse technology using proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced late-breaking...
Business Wire·2d ago
News Placeholder
Pulse Biosciences nPulse Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced its...
Business Wire·4d ago
News Placeholder
Mizuho Initiates Coverage on Pulse Biosciences (NASDAQ:PLSE)
Mizuho started coverage on shares of Pulse Biosciences in a research report on Friday. They issued an "outperform" rating and a $25.00 price target on the stock...
MarketBeat·8d ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 1.4% - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 1.4% - Here's Why...
MarketBeat·22d ago
News Placeholder
Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...
Business Wire·1mo ago
News Placeholder
Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced plans...
Business Wire·1mo ago
News Placeholder
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, today announced that...
Business Wire·2mo ago
News Placeholder
PLSE Wins FDA IDE Approval to Launch nPulse AF Ablation Study Trial
PLSE has secured FDA IDE approval to launch its nPulse AF ablation study.
Zacks·2mo ago
News Placeholder
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5% - Here's What Happened
Pulse Biosciences (NASDAQ:PLSE) Trading 5% Higher - Time to Buy...
MarketBeat·2mo ago
<
1
2
...
>

Latest PLSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.